Neogen (NEOG) came into focus after a recent move in its share price, with the stock last closing at $9.53. For investors, that price helps frame the discussion around value and expectations.
See our latest analysis for Neogen.
That recent move sits within a mixed picture, with a strong year to date share price return of 36.14% and a 1 year total shareholder return of 68.97% contrasting with a 3 year total shareholder return of 44.46% and a 5 year total shareholder return of 79.38%. This suggests that earlier momentum has faded even as sentiment has improved more recently.
If you are comparing Neogen with other ideas in the market, this could be a useful moment to broaden your search and check out 17 top founder-led companies
So with recent returns strong but revenue slightly lower and the company still reporting a loss, is Neogen quietly trading at a discount to its estimated value, or is the market already pricing in future growth?
Most Popular Narrative: 20.6% Undervalued
Neogen's fair value in the most followed narrative is set at $12, compared with the last close at $9.53. This puts the spotlight firmly on what is baked into those assumptions.
Operational improvements and automation at the new Petrifilm production facility, alongside targeted actions to reduce inefficiencies in sample collection and inventory management, are expected to drive gross margin and EBITDA margin improvements over the coming quarters as execution stabilizes and overhead absorption rates improve.
The core of this valuation hinges on how far margins can shift from deep losses toward typical industry levels. At the same time, revenue expectations remain restrained and the implied future earnings multiple stays comfortably above sector norms.
Result: Fair Value of $12 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the story can change quickly if integration issues around the 3M Food Safety assets or ongoing macro and trade pressures keep margins weak and revenue under strain.
Find out about the key risks to this Neogen narrative.
Next Steps
If this mix of risks and opportunities feels finely balanced, act while the data is fresh in your mind. Weigh both sides by checking the 2 key rewards and 1 important warning sign
Looking for more investment ideas?
Do not stop at one stock when there are plenty of other opportunities worth a closer look on the Simply Wall Street Screener.
- Spot potential bargains early by checking the screener containing 25 high quality undiscovered gems before they gain wider attention.
- Prioritise resilience by scanning the 72 resilient stocks with low risk scores for companies with steadier risk profiles.
- Focus on financial strength by reviewing the solid balance sheet and fundamentals stocks screener (44 results) so you are not caught out by weak balance sheets.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com